KRAS and lung carcinoma: Two small molecules targeting KRAS-G12C, namely Amgen (AMG510-Sotorasib) and Mirati (MRTX849-Adagrasib) bind to the allosteric switch-II pocket and covalently link the cysteine residue and the acrylamide group of the KRAS G12C inhibitor, were recently approved for clinical use in docetaxel-pretreated lung cancer patients [3,4].